



US009572866B2

(12) **United States Patent**  
**Vale, Jr. et al.**

(10) **Patent No.:** **US 9,572,866 B2**  
(45) **Date of Patent:** **Feb. 21, 2017**

(54) **UROCORTIN 2 ANALOGS AND USES THEREOF**

2007/0042954 A1 2/2007 Chen et al.  
2007/0191592 A1 8/2007 Vale, Jr. et al.  
2008/0161235 A1 7/2008 Chen et al.

(71) Applicants: **Research Development Foundation,**  
Carson City, NV (US); **Research Development Foundation,** Carson City, NV (US)

#### FOREIGN PATENT DOCUMENTS

WO WO 2008/047241 4/2008

(72) Inventors: **Wylie W. Vale, Jr.; Joan M. Vaughan,**  
San Diego, CA (US); **Cindy Donaldson,** San Diego, CA (US);  
**Wolfgang Fischer,** Encinitas, CA (US);  
**Jean E. F. Rivier,** La Jolla, CA (US)

#### OTHER PUBLICATIONS

(73) Assignee: **Research Development Foundation,**  
Carson City, NV (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/802,812**

(22) Filed: **Jul. 17, 2015**

(65) **Prior Publication Data**

US 2015/0315257 A1 Nov. 5, 2015

#### Related U.S. Application Data

(62) Division of application No. 13/392,828, filed as application No. PCT/US2010/046890 on Aug. 27, 2010, now abandoned.

(60) Provisional application No. 61/237,995, filed on Aug. 28, 2009.

(51) **Int. Cl.**  
**C07K 14/47** (2006.01)  
**A61K 38/22** (2006.01)  
**C07K 14/575** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **A61K 38/2228** (2013.01); **C07K 14/4705**  
(2013.01); **C07K 14/57509** (2013.01); **Y10T**  
**428/13** (2015.01)

(58) **Field of Classification Search**  
None

See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

6,214,797 B1 4/2001 Vale, Jr. et al.  
6,353,152 B1 3/2002 Lee et al.  
6,838,274 B2 1/2005 Vale, Jr. et al.  
7,141,546 B1 11/2006 Rivier et al.  
7,223,846 B2 5/2007 Vale, Jr. et al.  
7,459,427 B2 12/2008 Vale, Jr. et al.  
7,488,865 B2 2/2009 Lee et al.  
7,507,794 B2 3/2009 Chen et al.  
2002/0127221 A1\* 9/2002 Vale, Jr. .... C07K 14/57509  
424/94.63  
2003/0032587 A1 2/2003 Vale, Jr. et al.  
2005/0191650 A1 9/2005 Vale, Jr. et al.

Isfort et al. *Peptides*, 27 (2006) 1806-1813.\*  
Ehrendgruber et al. *Mol Cell Neuroscience*, 17, 855-871 (2001).  
"Neurocrine Biosciences announces initiation of phase I trial with urocortin 2 for congestive heart failure," *Press Release—Neurocrine Biosciences, Inc.*, 2004.  
"Neurocrine Biosciences announces urocortin 2 phase II study results in patients with acute decompensated heart failure," *Press Release—Neurocrine Biosciences, Inc.*, 2012.  
"Overcoming peptide problems by design," Technical Note PT2-009-1, *Peptides and Immunology*, Mimotopes, pp. 1-3, 2009.  
"Primary structure," retrieved from [http://en.wikipedia.org/wiki/Primary\\_structure](http://en.wikipedia.org/wiki/Primary_structure), retrieved on Mar. 18, 2009.  
"UniProtKB/Swiss-Prot. Q99ML8 (UNC2\_MOUSE)," retrieved from <http://www.uniprot.org/uniprot/Q99ML8>, last modified Jul. 9, 2014.  
Baram, et al., "The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist," *Brain Res.*, 770:89-95, 1997.  
Campbell et al., "A protein's shape depends on four levels of structure," Unit 1, *The Life of the Cell, Biology Concepts & Connections*, 5<sup>th</sup> Edition, 2006.  
Cervini, et al., "Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions," *J. Med. Chem.*, 42:761-8, 1999.  
Chan et al. "Urocortin-2 infusion in acute decompensated heart failure—Findings from the UNICORN study (Urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy," *JACC: Heart Failure*, 1(5):433-441, 2013.  
Chen et al., "Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle," *PNAS*, 103(44):16580-16585, 2006.  
Chen, et al., "Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids," *Endocrinology*, 145:2445-57, 2004.  
Fekete and Zorrilla, "Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs," *Front. Neuroendocrinol.*, 28:1-27, 2008.

(Continued)

*Primary Examiner* — Amber D Steele

*Assistant Examiner* — Schuyler Milton

(74) *Attorney, Agent, or Firm* — Parker Highlander PLLC

(57) **ABSTRACT**

Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention.

**19 Claims, No Drawings**